The FDA last week approved Incyte Corp.’s Zynyz for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare form of skin cancer. The PD-1 inhibitor will join oncology heavyweights in MCC market basket — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. Under the medial benefit, Opdivo is currently the most advantaged MCC therapy, holding covered or better status for 89% of all insured lives. Keytruda follows closely behind at 88%.
SOURCE: MMIT Analytics, as of 3/27/23